| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Karina K Kedzior, Johanna C Badcock, Mathew T Martin-Iverso. Validity and consistency of self-reports regarding substance use in general research volunteers, including regular cannabis users and schizophrenia patients. Substance use & misuse. vol 41. issue 5. 2006-10-31. PMID:16603458. |
validity and consistency of self-reports regarding substance use in general research volunteers, including regular cannabis users and schizophrenia patients. |
2006-10-31 |
2023-08-12 |
human |
| Karina K Kedzior, Johanna C Badcock, Mathew T Martin-Iverso. Validity and consistency of self-reports regarding substance use in general research volunteers, including regular cannabis users and schizophrenia patients. Substance use & misuse. vol 41. issue 5. 2006-10-31. PMID:16603458. |
the participants included regular cannabis users and schizophrenia patients. |
2006-10-31 |
2023-08-12 |
human |
| Antonio Waldo Zuardi, Jaime E C Hallak, Serdar Murat Dursun, Sílvio L Morais, Rafael Faria Sanches, Richard E Musty, José Alexandre S Cripp. Cannabidiol monotherapy for treatment-resistant schizophrenia. Journal of psychopharmacology (Oxford, England). vol 20. issue 5. 2006-10-19. PMID:16401651. |
cannabidiol monotherapy for treatment-resistant schizophrenia. |
2006-10-19 |
2023-08-12 |
Not clear |
| Karina K Kedzior, Mathew T Martin-Iverso. Chronic cannabis use is associated with attention-modulated reduction in prepulse inhibition of the startle reflex in healthy humans. Journal of psychopharmacology (Oxford, England). vol 20. issue 4. 2006-08-18. PMID:16174673. |
regardless of a wide research interest the nature of a relationship between cannabis use and schizophrenia is controversial. |
2006-08-18 |
2023-08-12 |
Not clear |
| Maria C Jockers-Scherübl, Johannes Rentzsch, Heidi Danker-Hopfe, Nicole Radzei, Falk Schürer, Sharif Bahri, Rainer Hellwe. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neuroscience letters. vol 400. issue 3. 2006-08-18. PMID:16540246. |
adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. |
2006-08-18 |
2023-08-12 |
Not clear |
| Maria C Jockers-Scherübl, Johannes Rentzsch, Heidi Danker-Hopfe, Nicole Radzei, Falk Schürer, Sharif Bahri, Rainer Hellwe. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neuroscience letters. vol 400. issue 3. 2006-08-18. PMID:16540246. |
in a previous study we demonstrated an earlier disease onset and significantly higher serum ngf concentrations in drug-naïve schizophrenic patients with previous long-term cannabis abuse than in schizophrenics without cannabis abuse or cannabis abusers without schizophrenia. |
2006-08-18 |
2023-08-12 |
Not clear |
| Maria C Jockers-Scherübl, Johannes Rentzsch, Heidi Danker-Hopfe, Nicole Radzei, Falk Schürer, Sharif Bahri, Rainer Hellwe. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neuroscience letters. vol 400. issue 3. 2006-08-18. PMID:16540246. |
serum ngf measured in 114 treated schizophrenic patients (schizophrenia alone, n=66; schizophrenia plus cannabis abuse, n=42; schizophrenia plus multiple substance abuse, n=6) no longer differed significantly among those groups and from the control groups (healthy controls, n=51; cannabis controls, n=24; multiple substance controls, n=6). |
2006-08-18 |
2023-08-12 |
Not clear |
| Maria C Jockers-Scherübl, Johannes Rentzsch, Heidi Danker-Hopfe, Nicole Radzei, Falk Schürer, Sharif Bahri, Rainer Hellwe. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neuroscience letters. vol 400. issue 3. 2006-08-18. PMID:16540246. |
these results were confirmed by an additional prospective study in 28 patients suffering from schizophrenia (s) or schizophrenia with cannabis abuse (sc). |
2006-08-18 |
2023-08-12 |
Not clear |
| Paul C Fletcher, Garry D Hone. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends in cognitive sciences. vol 10. issue 4. 2006-07-13. PMID:16531099. |
in this respect, ketamine and tetrahydrocannabinol (cannabis) are coming under increasing scrutiny as models for schizophrenia. |
2006-07-13 |
2023-08-12 |
Not clear |
| Paul C Fletcher, Garry D Hone. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends in cognitive sciences. vol 10. issue 4. 2006-07-13. PMID:16531099. |
memory deficits are pronounced in schizophrenia and we focus upon patterns of working and episodic memory impairment produced by ketamine and cannabis, identifying overlaps between drug and illness. |
2006-07-13 |
2023-08-12 |
Not clear |
| Steven R Laviolette, Anthony A Grac. Cannabinoids Potentiate Emotional Learning Plasticity in Neurons of the Medial Prefrontal Cortex through Basolateral Amygdala Inputs. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 24. 2006-07-11. PMID:16775133. |
in addition, cannabis use is a primary risk factor for schizophrenia in susceptible individuals and can potently modulate the emotional salience of sensory stimuli. |
2006-07-11 |
2023-08-12 |
rat |
| Sharon Monterrubio, Nadia Solowij, Barbara J Meyer, Nigel Turne. Fatty acid relationships in former cannabis users with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 2. 2006-06-08. PMID:16236415. |
fatty acid relationships in former cannabis users with schizophrenia. |
2006-06-08 |
2023-08-12 |
Not clear |
| Sharon Monterrubio, Nadia Solowij, Barbara J Meyer, Nigel Turne. Fatty acid relationships in former cannabis users with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 2. 2006-06-08. PMID:16236415. |
abnormalities in the fatty acid (fa)-based endocannabinoid lipid signaller anandamide, and prevalent cannabis use, have been found to be associated with schizophrenia and may potentially alter stress mechanisms. |
2006-06-08 |
2023-08-12 |
Not clear |
| Sharon Monterrubio, Nadia Solowij, Barbara J Meyer, Nigel Turne. Fatty acid relationships in former cannabis users with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 2. 2006-06-08. PMID:16236415. |
future research may determine whether these fas are involved in hypothesised links between anandamide abnormalities, cannabis use and stress in schizophrenia. |
2006-06-08 |
2023-08-12 |
Not clear |
| S Potvin, T Pampoulova, A Mancini-Marië, O Lipp, R-H Bouchard, E Sti. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. Journal of neurology, neurosurgery, and psychiatry. vol 77. issue 6. 2006-05-25. PMID:16705205. |
we studied 41 outpatients with schizophrenia (based on dsm-iv criteria), who were divided into two groups: with (n = 17) and without (n = 24) a substance use disorder (alcohol, cannabis, and/or cocaine). |
2006-05-25 |
2023-08-12 |
Not clear |
| John Macleod, George Davey Smith, Matthew Hickma. Does cannabis use cause schizophrenia? Lancet (London, England). vol 367. issue 9516. 2006-04-13. PMID:16581402. |
does cannabis use cause schizophrenia? |
2006-04-13 |
2023-08-12 |
Not clear |
| Marta Di Forti, Robin McGregor Murra. Cannabis consumption and risk of developing schizophrenia: myth or reality? Epidemiologia e psichiatria sociale. vol 14. issue 4. 2006-03-21. PMID:16396425. |
cannabis consumption and risk of developing schizophrenia: myth or reality? |
2006-03-21 |
2023-08-12 |
Not clear |
| Mark Weiser, Shlomo No. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in clinical neuroscience. vol 7. issue 1. 2006-01-13. PMID:16060598. |
interpreting the association between cannabis use and increased risk for schizophrenia. |
2006-01-13 |
2023-08-12 |
Not clear |
| Mark Weiser, Shlomo No. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in clinical neuroscience. vol 7. issue 1. 2006-01-13. PMID:16060598. |
recent longitudinal studies from sweden, the netherlands, new zealand, and israel report that cannabis use during childhood and adolescence doubles the risk of later appearance of psychosis or schizophrenia. |
2006-01-13 |
2023-08-12 |
Not clear |
| Mark Weiser, Shlomo No. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in clinical neuroscience. vol 7. issue 1. 2006-01-13. PMID:16060598. |
thus, an alternative explanation of the association between cannabis use and schizophrenia might be that pathology of the cannabinoid system in schizophrenia patients is associated with both increased rates of cannabis use and increased risk for schizophrenia, without cannabis being a causal factor for schizophrenia. |
2006-01-13 |
2023-08-12 |
Not clear |